IRIS UniCatt

Papa, Alfredo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.066
AS - Asia 5.429
EU - Europa 5.153
SA - Sud America 1.070
Continente sconosciuto - Info sul continente non disponibili 237
AF - Africa 146
OC - Oceania 4
Totale 20.105
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.823
SG - Singapore 2.452
DE - Germania 1.644
CN - Cina 1.377
BR - Brasile 855
SE - Svezia 764
IT - Italia 672
FR - Francia 492
VN - Vietnam 430
UA - Ucraina 399
GB - Regno Unito 283
IE - Irlanda 218
IN - India 199
FI - Finlandia 172
JP - Giappone 172
ID - Indonesia 171
CA - Canada 141
BD - Bangladesh 139
RU - Federazione Russa 128
TR - Turchia 90
AR - Argentina 85
ES - Italia 75
HK - Hong Kong 75
PL - Polonia 73
KR - Corea 51
IQ - Iraq 47
BE - Belgio 45
ZA - Sudafrica 45
MX - Messico 44
NL - Olanda 44
EC - Ecuador 40
IR - Iran 31
AT - Austria 30
PK - Pakistan 30
SA - Arabia Saudita 27
VE - Venezuela 25
CO - Colombia 22
MA - Marocco 18
LT - Lituania 16
CZ - Repubblica Ceca 15
JM - Giamaica 15
JO - Giordania 15
RO - Romania 14
AE - Emirati Arabi Uniti 13
EG - Egitto 13
CI - Costa d'Avorio 12
CL - Cile 12
IL - Israele 12
TN - Tunisia 12
UZ - Uzbekistan 12
KE - Kenya 10
CR - Costa Rica 9
DZ - Algeria 9
NP - Nepal 9
AZ - Azerbaigian 8
EU - Europa 8
HU - Ungheria 8
OM - Oman 8
PE - Perù 8
PH - Filippine 8
PY - Paraguay 8
UY - Uruguay 8
CH - Svizzera 7
BG - Bulgaria 6
ET - Etiopia 6
TW - Taiwan 6
BA - Bosnia-Erzegovina 5
BB - Barbados 5
GR - Grecia 5
MY - Malesia 5
BH - Bahrain 4
BZ - Belize 4
CG - Congo 4
EE - Estonia 4
KZ - Kazakistan 4
LV - Lettonia 4
PT - Portogallo 4
RS - Serbia 4
TT - Trinidad e Tobago 4
AL - Albania 3
AO - Angola 3
AU - Australia 3
BO - Bolivia 3
BY - Bielorussia 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
GA - Gabon 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
LK - Sri Lanka 3
MD - Moldavia 3
MM - Myanmar 3
MN - Mongolia 3
NI - Nicaragua 3
PA - Panama 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CY - Cipro 2
GE - Georgia 2
GP - Guadalupe 2
Totale 19.830
Salva come PNG Salva come JPEG
Città #
Singapore 1.336
Chandler 921
Ashburn 836
San Jose 738
New York 285
Jacksonville 260
Beijing 250
Dublin 212
Los Angeles 211
San Mateo 191
Hangzhou 173
Hefei 154
Jakarta 150
Tokyo 150
Lauterbourg 147
Ho Chi Minh City 137
Ann Arbor 127
Boston 122
Milan 121
Wilmington 117
Nanjing 115
Dearborn 111
Munich 106
Hanoi 103
The Dalles 102
Frankfurt am Main 100
Dallas 98
Nürnberg 92
Cattolica 82
Buffalo 80
Moscow 72
Princeton 72
Hong Kong 70
Santa Clara 70
São Paulo 69
Rome 68
Houston 58
Council Bluffs 56
Boardman 55
Marseille 55
Helsinki 51
Chicago 50
Izmir 49
Atlanta 48
Redwood City 48
Nanchang 46
Bremen 45
Brussels 43
Seoul 43
Lawrence 42
Toronto 42
Redmond 41
Seattle 41
Kent 38
Woodbridge 37
Warsaw 36
London 35
Brooklyn 34
Montreal 33
Phoenix 32
San Francisco 32
Paris 29
Shanghai 29
Fairfield 28
Changsha 27
Rio de Janeiro 27
Stockholm 27
Norwalk 26
Nuremberg 26
Kunming 25
Orem 25
Turku 25
Augusta 24
Denver 24
Kraków 24
Baghdad 23
Belo Horizonte 23
Hebei 23
Detroit 22
Lappeenranta 22
Pune 22
Shenyang 22
Trieste 22
Da Nang 21
Johannesburg 21
Lancaster 21
North Bergen 21
Andover 20
Guangzhou 20
Mountain View 20
Charlotte 19
Chennai 19
Poplar 19
St Louis 19
Tianjin 19
Jiaxing 18
Vienna 18
Düsseldorf 17
Kish 17
Amsterdam 16
Totale 10.008
Salva come PNG Salva come JPEG
Nome #
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 372
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis 346
When to Perform a Colonoscopy in Diverticular Disease and Why: A Personalized Approach 270
Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis. 269
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. 256
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 230
Early atherosclerosis in patients with inflammatory bowel disease. 216
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 216
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update 212
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 210
Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression? 209
Assessment of neurological manifestations in hospitalized patients with COVID-19 203
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 199
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 196
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 196
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 193
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. 193
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 187
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis 184
Federated learning in inflammatory bowel disease: The future of privacy-preserving Artificial Intelligence 182
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 182
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 179
Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD) 179
Intercellular adhesion molecule 1 gene polymorphisms in inflammatory bowel disease 176
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 174
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 172
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations. 170
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 169
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 162
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 160
Use of infliximab in particular clinical settings: management based on current evidence. 157
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. 157
Development and validation of predictive assessment of complicated diverticulitis score 156
-Extraintestinal manifestations in inflammatory Bowel disease. 154
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 154
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 153
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 152
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 152
A) Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice? 150
Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease 149
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 149
Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools 148
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. 148
The dica endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists: An international study 148
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 146
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 144
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 143
A novel pathogenic role for microvasculature in inflammatory bowel disease. 142
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 142
Endoscopic Management of Strictures in Crohn’s Disease: An Unsolved Case 137
Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 136
Biological therapies for inflammatory bowel disease: research drives clinics. 135
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 135
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action 134
Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events 133
Effect of moderate and heavy alcohol consumption on intestinal transit time 133
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 133
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease 133
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 132
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center 130
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease 130
A) Platelets: new players in the mucosal scenario of inflammatory bowel disease. 129
Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. 126
Crohn's Disease: Radiological Answers to Clinical Questions and Review of the Literature 124
A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab. 124
Microbiota Composition in Diverticular Disease: Implications for Therapy 123
A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn’s disease patients 123
Cytomegalovirus Infection: An Underrated Target in Inflammatory Bowel Disease Treatment 122
Can we predict the efficacy of anti-TNF-α agents? 122
A) Review article: inherited thrombophilia in inflammatory bowel disease. 121
Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer. 121
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 120
The Role of Microbiota in Pancreatic Cancer 118
Histologic Disease Persists beyond Mucosal Healing and Could Predict Reactivation in Ulcerative Colitis 118
CT and MRI Evaluations in Crohn's Complications: A Guide for the Radiologist 117
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 116
-Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation 116
Differentiation affects the release of exosomes from colon cancer cells and their ability to modulate the behavior of recipient cells 116
Radiomics could predict surgery at 10 years in Crohn's disease 115
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 114
Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells 113
Mucosal healing in ulcerative colitis: surveillance or colectomy? 112
How to face the advent of sars-cov-2 vaccination in ibd patients: Another task for gastroenterologists 111
Gut dysbiosis-related thrombosis in inflammatory bowel disease: Potential disease mechanisms and emerging therapeutic strategies 110
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 110
Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells 110
Role of Helicobacter pylori CagA+ infection in determining oxidative DNA damage in gastric mucosa 109
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 108
Hot topics in surgical management of acute diverticulitiss 107
Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery 107
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 106
PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system. 106
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 105
Infliximab does not increase colonic cancer risk associated to murine chronic colitis 105
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 104
Microbiota Composition in Diverticular Disease: Implications for Therapy 103
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 103
Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease 102
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 101
New therapeutic approach in inflammatory bowel disease. 100
Totale 15.124
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.505
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.505
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022919 0 0 21 111 47 21 12 214 38 68 168 219
2022/20232.307 299 297 157 418 135 301 88 188 263 45 74 42
2023/20241.230 57 319 53 70 42 174 68 43 45 77 135 147
2024/20252.679 60 88 249 68 238 81 111 124 329 286 570 475
2025/20267.309 1.104 241 442 866 1.205 316 1.236 359 551 509 253 227
2026/20271.487 561 923 3 0 0 0 0 0 0 0 0 0
Totale 20.105